Premium
Atypical Neuroleptic Malignant Syndrome Associated with Olanzapine
Author(s) -
Reeves Roy R.,
Torres Raphael A.,
Liberto Vincent,
Hart Roy H.
Publication year - 2002
Publication title -
pharmacotherapy: the journal of human pharmacology and drug therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.227
H-Index - 109
eISSN - 1875-9114
pISSN - 0277-0008
DOI - 10.1592/phco.22.8.641.33211
Subject(s) - neuroleptic malignant syndrome , olanzapine , muscle rigidity , antipsychotic , atypical antipsychotic , medicine , adverse effect , pediatrics , psychiatry , psychology , intensive care medicine , anesthesia , schizophrenia (object oriented programming)
Neuroleptic malignant syndrome (NMS) is a potentially life‐threatening adverse effect of antipsychotic agents. It generally is characterized by fever, altered mental status, rigidity, and autonomic dysfunction. A 53‐year‐old man developed NMS without rigidity while taking olanzapine. Such atypical cases may support either a spectrum concept of NMS or the theory that NMS secondary to atypical antipsychotics differs from that caused by conventional neuroleptics. More flexible diagnostic criteria than currently mandated by the the Diagnostic and Statistical Manual of Mental Disorders, Fourth Revision , may be warranted.